BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study

BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.